Results 171 to 180 of about 93,615 (295)

Treatment‐Related Risk Factors for Diabetes Mellitus in Childhood Cancer Survivors—A Case‐Cohort Study Within Adult Life After Childhood Cancer in Scandinavia (ALiCCS)

open access: yesPediatric Blood &Cancer, Volume 72, Issue 8, August 2025.
ABSTRACT The aim was to identify treatment‐related risk factors for diabetes in 5‐year survivors of childhood cancer (CCS). This case‐cohort study within Adult Life after Childhood Cancer in Scandinavia (ALiCCS) included 140 CCS with diabetes and a subcohort of 390 randomly selected CCS.
Line Kenborg   +18 more
wiley   +1 more source

Long‐Term Projections of Childhood Cancer Incidence and Prevalence in Ontario, Canada Until 2040

open access: yesPediatric Blood &Cancer, Volume 72, Issue 8, August 2025.
ABSTRACT Background The prevalence of childhood cancer continues to rise due to increases in cancer incidence and advances in treatment, leading to better survival. We generated epidemiologic projections for childhood cancer, by cancer type, in Ontario, Canada, until 2040.
Alexandra Moskalewicz   +3 more
wiley   +1 more source

Normal bone maturation in GH and somatomedin (SM) deficient children with pituitary irradiation for retinoblastoma [PDF]

open access: bronze, 1981
R Pomarède   +5 more
openalex   +1 more source

hTERT Increases TRF2 to Induce Telomere Compaction and Extend Cell Replicative Lifespan

open access: yesAging Cell, Volume 24, Issue 8, August 2025.
In contrast to the dogma that a subset of short telomeres initiates senescence, hTERT variants unable to maintain telomere length block senescence by stabilizing TRF2 via inhibiting upstream E3 ubiquitin ligases. This noncanonical hTERT function also compacts telomeres and blocks senescence‐associated DNA damage signaling. Cancer cells expressing hTERT
Nancy Adam   +15 more
wiley   +1 more source

Unlocking the power of immune checkpoint inhibitors: Targeting YAP1 reduces anti‐PD1 resistance in skin cutaneous melanoma

open access: yesBritish Journal of Pharmacology, Volume 182, Issue 16, Page 3903-3922, August 2025.
Abstract Background and Purpose Immune checkpoint inhibitors, such as anti­PD1, revolutionized melanoma treatment. However, resistance and low response rates remain problems. Our goal was to pinpoint actionable biomarkers of resistance to anti‐PD1 treatment and verify therapeutic effectiveness in vivo.
Szonja Anna Kovács   +13 more
wiley   +1 more source

Retinoblastoma and Neuroblastoma Predisposition and Surveillance

open access: yesClinical Cancer Research, 2017
J. Kamihara   +13 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy